PHARMACYCLICS INC. / ABBVIE INC / Public / Acquisition / £13661m

Synopsis

Acquisition by AbbVie of Pharmacyclics, a biopharmaceutical company developing innovative products to treat cancer, atherosclerosis and other diseases.

Principals

target

Pharmacyclics Inc.

bidder

Abbvie

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

jp morgan

HQ - New York

financial advisors

target

2800

Deals

£ 6,390.72 B

Total Value

latham & watkins

HQ - New York, United States

legal advisors

target

5445

Deals

£ 3,505.44 B

Total Value

centerview partners

HQ - New York

financial advisors

target

554

Deals

£ 1,917.17 B

Total Value